Technology
Cheche Group Reports Third Quarter 2024 Unaudited Financial Results
Published
2 years agoon
By
BEIJING, Nov. 26, 2024 /PRNewswire/ — Cheche Group Inc. (NASDAQ: CCG) (“Cheche”, the “Company” or “we”), China’s leading auto insurance technology platform, today announced its unaudited financial results for the third quarter ended September 30, 2024.
Financial and Operational Highlights
Net Revenues for the quarter increased 3.3% year-over-year to RMB850.5 million (US$121.2 million), while net revenues for the first nine months of 2024 increased 2.3% over the comparable prior year period to RMB2.5 billion (US$354.8 million). Net Income for the quarter was RMB4.1 million (US$0.6 million), compared to a net loss of RMB55.4 million for the prior-year quarter, while net loss for the first nine months of 2024 decreased 60.2% to RMB50.8 million (US$7.2 million) over the prior-year period.Adjusted Net Income (1) for the quarter was RMB2.6 million (US$0.4 million), compared to an adjusted net loss of RMB0.6 million for the prior-year quarter, while adjusted net loss for the first nine months of 2024 decreased 23.0% to RMB21.8 million (US$3.1 million), compared to the prior-year period.Total written premiums placed for the quarter increased 4.0% to RMB5.9 billion (US$0.8 billion) compared to the prior-year period, while total written premiums placed for the first nine months of 2024 increased 4.1% over the comparable prior-year period to RMB16.9 billion (US$2.4 billion).Total number of policies issued for the quarter increased 5.0% to 4.2 million from 4.0 million for the prior-year quarter, while the total number of policies issued over the first nine months of 2024 increased 11.9% over the comparable prior-year period to 12.2 million.Partnerships with New Energy Vehicle (NEV) companies (2) numbered 14 in the quarter and led to 292,000 embedded policies with corresponding written premium of RMB884.2 million (US$126.0 million), representing an increase of 149.6% and 121.6 % compared to the prior-year quarter, respectively. Embedded policies and corresponding written premium for the first nine months of 2024 reached 636,000 and RMB1.9 billion (US$273.2 million), respectively, representing growth of 144.6 % for policies embedded and 104.2% for written premium compared to the prior-year period.
(1) Adjusted Net Loss/Income is a non-GAAP measure. For further information on the non-GAAP financial measures presented above, see the “Non-GAAP Financial Measures” section below.
(2) The rapid growth of the NEV market has created new opportunities for auto insurance offerings and propelled revenue growth of auto insurance providers. Cheche started collaborating with NEV manufacturers in 2022, which yielded considerable results in 2023. Cheche believes that the further development of the NEV market and the introduction of innovative NEV auto insurance solutions will further fuel the revenue contribution of its partnership with NEV manufacturers. The management of Cheche utilizes the number of partnerships with NEV manufacturers, the number of insurance policies embedded in the new NEV deliveries, and the number of corresponding premiums generated from such embedded policies as the primary operating metrics to evaluate its business. It presents such operating metrics for investors to better understand and assess Cheche’s business.
Management Comments
“We are proud to announce that Cheche reported net income profitability for the first time on both a GAAP and adjusted net income basis. This quarter’s milestone substantiates the merit of our business model and the growing conviction in our value proposition,” said Lei Zhang, Founder, CEO, and Chairman of Cheche Group. “We continue to work with both NEV manufacturers and insurers to leverage advanced data analysis, delivering tools that will reward responsible drivers, reduce fraud, and bring efficiencies to claims processing to support profitability, transparency, and affordability as the transition to automated mobility accelerates.
Mr. Zhang continued, “With China producing 48% more NEVs in September over the prior year, according to China Association of Automobile Manufacturers, and NEV sales again surpassing traditional fuel car sales in the same month, our innovative platform will continue to meet the evolving insurance needs of car owners, manufacturers, and insurers.”
Unaudited Third Quarter 2024 Financial Results
Net Revenues were RMB850.5 million (US$121.2 million), representing a 3.3% year-over-year increase from the prior-year quarter. The growth was driven by increased insurance transactions conducted through Cheche’s platform by referral and third-party platform partners.
Cost of Revenues increased 3.0% year-over-year to RMB808.1 million (US$115.2 million) from the prior-year quarter, consistent with the growth of business volume and net revenues.
Selling and Marketing Expenses decreased 53.6% to RMB18.1 million (US$2.6 million) from RMB39.0 million in the prior-year quarter, mainly due to the decrease in share-based compensation expenses and staff cost. Excluding share-based compensation expenses, selling and marketing expenses were RMB17.4 million (US$2.5 million), a decrease of 6.5% compared to the prior-year quarter.
General and Administrative Expenses decreased 41.3% to RMB20.4 million (US$2.9 million) from RMB34.8 million for the prior-year quarter, mainly due to the decrease in share-based compensation and professional service fees. Excluding share-based compensation and listing-related professional service fees, general and administrative expenses increased by RMB3.5 million from RMB15.0 million to RMB18.5 million (US$2.6 million), primarily due to the increase of post-listing professional service fees.
Research and Development Expenses decreased 24.5% to RMB10.2 million (US$1.4 million) from RMB13.5 million in the prior-year quarter. The change was mainly due to decreased share-based compensation expenses, partially offset by the increase of staff costs. Excluding share-based compensation expenses, research and development expenses decreased 8.8% to RMB9.8 million (US$1.4 million) from RMB10.8 million in the prior-year quarter.
Total Cost and Operating Expenses decreased by 1.8% to RMB856.8 million (US$122.1 million) from RMB872.0 million in the prior-year quarter, mainly due to the increased cost of revenues and the decrease in share-based compensation expenses. Excluding share-based compensation expenses, amortization of intangible assets related to the acquisition and listing-related professional service fees, total cost and operating expenses increased by 3.0% from the prior-year quarter.
Net Income for the quarter was RMB4.1 million (US$0.6 million), compared to a net loss of RMB55.4 million for the prior-year quarter. Excluding non-GAAP expenses, the Adjusted Net Income (1) for the quarter was RMB2.6 million (US$0.4 million), due to the improvement of operating results and the positive impact from foreign exchange rates, compared to an adjusted net loss of RMB0.6 million for the prior-year quarter.
Net Income attributable to Cheche’s shareholders was RMB4.1 million (US$0.6 million), compared to a net loss attributable to Cheche’s shareholders of RMB707.6 million for the prior-year quarter.
Adjusted Net Income attributable to Cheche’s shareholders was RMB2.6 million (US$0.4 million), compared to an adjusted net loss attributable to Cheche’s shareholders of RMB652.7 million for the prior-year quarter.
Net Income Per Share, basic and diluted, was RMB0.05 (US$0.01), compared to a net loss per share of RMB17.52, basic and diluted, for the prior-year quarter.
Adjusted Net Income Per Share, basic and diluted, was RMB0.03 (US$0.00), compared to an adjusted net loss per share of RMB16.16, basic and diluted, for the prior-year quarter.
3Q24 and Subsequent Business Highlights
On September 3, 2024, Cheche announced a partnership with Shanghai Jidu Automobile Company Limited (“JI YUE“) to further diversify its partner network with leaders in the NEV industry. Cheche successfully launched a system for JI YUE, creating channels for online and offline purchasing of auto and non-auto insurance products. The system is integrated into Cheche’s core platform and is equipped with resources to grow and strengthen JI YUE’s sales channels and enhance account settlement capabilities, among other functionalities.On September 12, 2024, Cheche announced a partnership with Laoyou Insurance Brokerage Co., Ltd. (“Laoyou Insurance”), a wholly controlled subsidiary of Great Wall Motor Company Limited (“GWM”), a top ten Chinese auto manufacturer. Cheche’s insurance solutions and mature transaction system have been gradually rolled out with GWM’s newly established direct-sales network in more than 20 cities nationwide. Cheche plans to develop a comprehensive insurance solution tailored for traditional automakers within one to two years.On October 1, 2024, Cheche announced a strategic partnership with The Tokio Marine & Nichido Fire Insurance Company (China) Limited (“TMNCH”), as Cheche continues to broaden its collaborations with insurance companies in China. Leveraging each other’s strengths, the two companies are working to develop specialized insurance products, services, and sales strategies. Cheche’s agreement with TMNCH is two pronged. This collaboration will enhance Cheche’s insurance service capabilities while offering increased scale for traditional automotive companies and pave the way for future partnerships with Japanese automotive companies.
Balance Sheet
As of September 30, 2024, the Company had RMB194.6 million (US$27.7 million) in total cash, cash equivalents and short-term investments.
Business Outlook
Cheche is affirming its full-year 2024 outlook:
Net Revenues are expected to range from RMB3.5 billion to RMB3.7 billion, representing an increase of 6.1% to 12.1%, compared to the full year of 2023.Total written premiums placed are expected to range from RMB24.5 billion to RMB26.5 billion, representing an increase of 8.4% to 17.3%, compared to the full year of 2023.
Conference Call
Cheche will host a webcast and conference call to discuss its third quarter 2024 results today at 8:00 a.m. EST. This earnings release and a related investor deck will be available prior to the event in the “Quarterly Results” section under “Financials,” while the live webcast will be available in the “Events” section under the “News & Events” header on the investor relations website at ir.chechegroup.com.
The dial-in numbers for the conference call will be as follows:
Participant (toll-free): 1-888-346-8982Participant (international): 1-412-902-4272Hong Kong LT: 852-301-84992Hong Kong Toll Free: 800-905945China Toll-Free: 4001-201203
Please dial in 10 to 15 minutes before the scheduled start time and request Cheche’s third quarter earnings call.
A webcast replay will be available for one year following the call.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the reader’s convenience. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.0176 to US$1.00, the exchange rate on September 30, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referenced could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.
About Cheche Group Inc.
Established in 2014 and headquartered in Beijing, China, Cheche is a leading auto insurance technology platform with a nationwide network of around 108 branches licensed to distribute insurance policies across 25 provinces, autonomous regions, and municipalities in China. Capitalizing on its leading position in auto insurance transaction services, Cheche has evolved into a comprehensive, data-driven technology platform that offers a full suite of services and products for digital insurance transactions and insurance SaaS solutions in China. Learn more at https://www.chechegroup.com/en.
Cheche Group Inc.:
Crocker Coulson
crocker.coulson@aummedia.org
(646) 652-7185
Non-GAAP Financial Measures
Cheche has provided non-GAAP financial measures in this press release that have not been prepared in accordance with generally accepted accounting principles (GAAP) in the United States.
Cheche uses adjusted cost of revenues, adjusted selling and marketing expenses, adjusted general and administrative expenses, adjusted research and development expenses, adjusted total cost and operating expenses, adjusted net loss/income, and adjusted net loss/income per share, which are non-GAAP financial measures, in evaluating our operating results and for financial and operational decision-making purposes.
Cheche defines adjusted total cost and operating expenses as total cost and operating expenses adjusted for the impact of share-based compensation, amortization of intangible assets related to the acquisition of Cheche Insurance Sales & Services Co., Ltd. (previously named Fanhua Times Sales and Service Co., Ltd), listing-related professional service fees and dispute resolution expenses, representing expenses Cheche incurred in a dispute with a certain security holder. Cheche defines adjusted net loss/income as net loss/income adjusted for the impact of share-based compensation expenses, amortization of intangible assets, and changes in fair value of amounts due to a related party related to the acquisition of Cheche Insurance Sales & Services Co., Ltd. (previously named Fanhua Times Sales and Service Co., Ltd), change in fair value of warrants, listing related professional service fees and dispute resolution expenses. Adjusted net loss/income per share, basic and diluted, is calculated as adjusted net loss/income divided by weighted-average ordinary shares outstanding.
Cheche believes that these non-GAAP financial measures help identify underlying trends in its business that could otherwise be distorted by the impact of share-based compensation expenses, amortization of intangible assets related to acquisition, and change in fair value of amounts due to a related party associated with the acquisition of Cheche Insurance Sales & Services Co., Ltd. (previously named Fanhua Times Sales and Service Co., Ltd), change in fair value of warrants, and listing related professional service fees and dispute resolution expenses. Cheche believes that such non-GAAP financial measures also provide useful information about its operating results, enhance the overall understanding of its past performance and future prospects, and allow for greater visibility with respect to key metrics used by its management in its financial and operational decision-making.
The non-GAAP financial measures are not defined under U.S. GAAP nor presented in accordance with U.S. GAAP. They should not be considered in isolation or construed as alternatives to net loss /income or any other measure of performance or as an indicator of Cheche’s operating performance. Further, these non-GAAP financial measures may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to the Company’s data. Cheche encourages investors and others to review the Company’s financial information in its entirety and not rely on a single financial measure. Investors are encouraged to compare the historical non-GAAP financial measures with the most directly comparable GAAP measures. Cheche mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating its performance.
Safe Harbor Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding projections, estimations, and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, the Company’s advantages and expected growth, and its ability to source and retain talent, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These statements involve risks, uncertainties, and other factors that may cause the Company’s actual results, activity levels, performance, or achievements to materially differ from those expressed or implied by these forward-looking statements. Further information regarding these and other risks, uncertainties, or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.
Unaudited Condensed Consolidated Balance Sheets (All amounts in thousands, except for share
and per share data)
December 31,
September 30,
September 30,
2023
2024
2024
RMB
RMB
USD
ASSETS
Current assets:
Cash and cash equivalents
243,392
131,110
18,683
Short-term investments
21,474
63,512
9,050
Accounts receivable, net
466,066
746,873
106,429
Prepayments and other current assets
49,321
41,829
5,961
Total current assets
780,253
983,324
140,123
Non-current assets:
Restricted Cash
5,000
5,000
712
Property, equipment and leasehold improvement, net
1,667
2,205
314
Intangible assets, net
8,050
6,475
923
Right-of-use assets
10,249
8,936
1,273
Goodwill
84,609
84,609
12,057
Other non-current assets
4,149
4,930
703
Total non-current assets
113,724
112,155
15,982
Total assets
893,977
1,095,479
156,105
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable
316,868
565,806
80,627
Short-term borrowings
20,000
15,000
2,137
Contract liabilities
4,295
2,524
360
Salary and welfare benefits payable
73,609
78,500
11,186
Tax payable
950
4,547
648
Amounts due to related party
55,251
–
–
Accrued expenses and other current liabilities
25,759
17,905
2,552
Short-term lease liabilities
3,951
4,270
608
Warrant
850
1
–
Total current liabilities
501,533
688,553
98,118
Non-current liabilities:
Amounts due to related party
–
44,420
6,330
Deferred tax liabilities
2,013
1,619
231
Long-term lease liabilities
5,398
3,960
564
Deferred revenue
1,432
1,432
204
Warrant
5,419
1,241
177
Total non-current liabilities
14,262
52,672
7,506
Total liabilities
515,795
741,225
105,624
Ordinary shares
5
6
1
Treasury stock
(1,025)
(1,025)
(146)
Additional paid-in capital
2,491,873
2,521,942
359,374
Accumulated deficit
(2,113,821)
(2,164,642)
(308,459)
Accumulated other comprehensive income/(loss)
1,150
(2,027)
(289)
Total Cheche’s shareholders’ equity
378,182
354,254
50,481
Total liabilities and shareholders’ equity
893,977
1,095,479
156,105
Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss)/Income
(All amounts in thousands, except for share and per share data)
For the Three Months Ended
For the Nine Months Ended
September 30,
September 30,
September 30,
September 30,
September 30,
September 30,
2023
2024
2024
2023
2024
2024
RMB
RMB
USD
RMB
RMB
USD
Net revenues
823,269
850,517
121,198
2,433,640
2,489,503
354,751
Cost and Operating expenses:
Cost of revenues
(784,782)
(808,079)
(115,150)
(2,336,761)
(2,382,364)
(339,484)
Selling and marketing expenses
(38,991)
(18,110)
(2,581)
(86,747)
(59,771)
(8,517)
General and administrative expenses
(34,809)
(20,422)
(2,910)
(84,503)
(82,175)
(11,710)
Research and development expenses
(13,465)
(10,166)
(1,449)
(44,768)
(28,691)
(4,088)
Total cost and operating expenses
(872,047)
(856,777)
(122,090)
(2,552,779)
(2,553,001)
(363,799)
Other expenses:
Interest income
1,212
1,753
250
2,695
5,010
714
Interest expense
(329)
(176)
(25)
(871)
(616)
(88)
Foreign exchange gains/(losses)
1,069
3,502
499
(5,265)
2,447
349
Government grants
2,685
243
35
9,925
477
68
Changes in fair value of warrant
(10,307)
992
141
(10,434)
4,368
622
Changes in fair value of amounts due
to related party
(1,086)
3,901
556
(4,922)
615
88
Others, net
(33)
6
1
(2)
186
27
(Loss)/income before income tax
(55,567)
3,961
565
(128,013)
(51,011)
(7,268)
Income tax credit
128
90
13
386
190
27
Net (loss)/income
(55,439)
4,051
578
(127,627)
(50,821)
(7,241)
Accretions to preferred shares
redemption value
(652,178)
–
–
(762,169)
–
–
Net (loss)/income attributable to the
Cheche’s ordinary shareholders
(707,617)
4,051
578
(889,796)
(50,821)
(7,241)
Net (loss)/income
(55,439)
4,051
578
(127,627)
(50,821)
(7,241)
Other comprehensive (loss)/income:
Foreign currency translation
adjustments, net of nil tax
(1,433)
(5,408)
(771)
5,977
(3,393)
(483)
Fair value changes of amounts due to
related party due to own credit risk
(104)
470
67
(404)
216
31
Total other comprehensive
(loss)/income
(1,537)
(4,938)
(704)
5,573
(3,177)
(452)
Total comprehensive loss
(56,976)
(887)
(126)
(122,054)
(53,998)
(7,693)
Net (loss)/income per ordinary
shares outstanding
Basic
(17.52)
0.05
0.01
(25.21)
(0.66)
(0.09)
Diluted
(17.52)
0.05
0.01
(25.21)
(0.66)
(0.09)
Weighted average number of
ordinary shares outstanding
Basic
40,396,693
79,396,465
79,396,465
35,297,133
77,324,958
77,324,958
Diluted
40,396,693
86,508,545
86,508,545
35,297,133
77,324,958
77,324,958
Reconciliation of GAAP Cost and Operating Expenses to Non-GAAP Cost and Operating
Expenses (Unaudited)
(All amounts in thousands)
For the Three Months Ended
For the Nine Months Ended
September
30,
September
30,
September
30,
September
30,
September
30,
September
30,
2023
2024
2024
2023
2024
2024
RMB
RMB
USD
RMB
RMB
USD
Cost of revenues
(784,782)
(808,079)
(115,150)
(2,336,761)
(2,382,364)
(339,484)
Add: Share-based compensation
expenses
114
3
–
187
9
1
Amortization of intangible assets related
to acquisition
525
525
75
1,575
1,575
224
Adjusted Cost of revenues
(784,143)
(807,551)
(115,075)
(2,334,999)
(2,380,780)
(339,259)
Selling and marketing expenses
(38,991)
(18,110)
(2,581)
(86,747)
(59,771)
(8,517)
Add: Share-based compensation
expenses
20,381
718
102
30,054
4,350
620
Adjusted Selling and marketing
expenses
(18,610)
(17,392)
(2,479)
(56,693)
(55,421)
(7,897)
General and administrative expenses
(34,809)
(20,422)
(2,910)
(84,503)
(82,175)
(11,710)
Add: Share-based compensation
expenses
10,334
1,898
270
25,689
24,044
3,426
Listing related professional expenses
9,435
–
–
14,972
–
–
Dispute resolution expenses (1)
–
–
–
–
2,355
336
Adjusted General and administrative
expenses
(15,040)
(18,524)
(2,640)
(43,842)
(55,776)
(7,948)
Research and development expenses
(13,465)
(10,166)
(1,449)
(44,768)
(28,691)
(4,088)
Add: Share-based compensation
expenses
2,688
334
48
11,462
1,667
238
Adjusted Research and development
expenses
(10,777)
(9,832)
(1,401)
(33,306)
(27,024)
(3,850)
Total cost and operating expenses
(872,047)
(856,777)
(122,090)
(2,552,779)
(2,553,001)
(363,799)
Adjusted total cost and operating
expenses
(828,570)
(853,299)
(121,595)
(2,468,840)
(2,519,001)
(358,954)
(1) represents expenses incurred by Cheche in connection with settling a dispute with a certain security holder,
which are not directly related to the core operations of Cheche’s business.
Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
(All amounts in thousands, except for share data and per share data)
For the Three Months Ended
For the Nine Months Ended
September
30,
September
30,
September
30,
September
30,
September
30,
September
30,
2023
2024
2024
2023
2024
2024
RMB
RMB
USD
RMB
RMB
USD
Net (loss)/income
(55,439)
4,051
578
(127,627)
(50,821)
(7,241)
Add: Share-based compensation expenses
33,517
2,953
420
67,392
30,070
4,285
Amortization of intangible assets related to acquisition
525
525
75
1,575
1,575
224
Listing related professional expenses
9,435
–
–
14,972
–
–
Changes in fair value of warrant
10,307
(992)
(141)
10,434
(4,368)
(622)
Changes in fair value of amounts due to related party
1,086
(3,901)
(556)
4,922
(615)
(88)
Dispute resolution expenses
–
–
–
–
2,355
336
Adjusted net (loss)/income
(569)
2,636
376
(28,332)
(21,804)
(3,106)
Accretions to preferred shares redemption value
(652,178)
–
–
(762,169)
–
–
Adjusted net (loss)/income attributable to
Cheche’s ordinary shareholders
(652,747)
2,636
376
(790,501)
(21,804)
(3,106)
Weighted average number of ordinary shares used
in computing non-GAAP adjusted net
(loss)/income per ordinary share
Basic
40,396,693
79,396,465
79,396,465
35,297,133
77,324,958
77,324,958
Diluted
40,396,693
86,508,545
86,508,545
35,297,133
77,324,958
77,324,958
Net (loss)/income per ordinary share
Basic
(17.52)
0.05
0.01
(25.21)
(0.66)
(0.09)
Diluted
(17.52)
0.05
0.01
(25.21)
(0.66)
(0.09)
Non-GAAP adjustments to net (loss)/income per
ordinary share
Basic
1.36
(0.02)
(0.01)
2.81
0.38
0.05
Diluted
1.36
(0.02)
(0.01)
2.81
0.38
0.05
Adjusted net (loss)/income per ordinary share
Basic
(16.16)
0.03
0.00
(22.40)
(0.28)
(0.04)
Diluted
(16.16)
0.03
0.00
(22.40)
(0.28)
(0.04)
View original content:https://www.prnewswire.com/news-releases/cheche-group-reports-third-quarter-2024-unaudited-financial-results-302316388.html
SOURCE Cheche Group Inc.
You may like
Technology
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
Published
3 minutes agoon
July 21, 2026By
The article explains how sterile compounded medications are prepared to reduce the risk of contamination and support safe, customized treatments.
AZLE, Texas, July 21, 2026 /PRNewswire/ — What does sterile compounding mean for medication safety? HelloNation has published an article explaining how sterile compounding helps pharmacies prepare highly specialized medications while adhering to strict contamination-prevention procedures.
The article features insights from Laura Temple, Compounding Pharmacist Expert and Owner of Laura’s Pharmacy in Azle, Texas. It explains that sterile compounding is a specialized process for preparing medications in carefully controlled environments designed to reduce the risk of contamination. Sterile compounded medications are often used for injections, eye drops, IV medications, and other therapies that require the highest levels of cleanliness and precision.
The HelloNation article explains that sterile compounded medications differ from commercially manufactured drugs because they are prepared individually for a patient’s unique medical needs. Physicians may prescribe compounded prescriptions when a patient requires a customized dosage, a combination medication, or a treatment not commercially available. Because these medications often bypass the body’s natural defenses, medication safety depends on strict preparation standards throughout the compounding process.
The article describes how pharmacies that provide sterile compounding rely on cleanroom environments equipped with filtered-air systems, specialized equipment, and contamination-prevention protocols. Pharmacists and technicians follow detailed gowning, sterilization, and handwashing procedures before handling medication ingredients. These measures are designed to support medication safety by limiting exposure to bacteria, particles, and other contaminants.
According to the article, environmental monitoring also plays a critical role in sterile compounding. Temperature control, air quality testing, and routine equipment inspections help maintain consistent preparation standards. The article notes that sterile compounded medications may undergo additional quality assurance checks before being dispensed to patients. These procedures help support both treatment effectiveness and patient safety.
The HelloNation article also explains that pharmacies performing sterile compounding are expected to follow USP guidelines established for sterile preparation. These USP guidelines outline requirements for cleanroom pharmacy operations, environmental testing, employee training, and quality assurance practices. The article emphasizes that maintaining compliance with USP guidelines helps reinforce contamination prevention and consistent preparation standards for compounded prescriptions.
Patients seeking sterile compounded medications may also look for pharmacies that participate in accreditation programs or are overseen by state boards. The article explains that these programs review safety procedures, documentation practices, and facility standards to help maintain medication safety. Regular environmental monitoring and staff competency evaluations are also identified as important safeguards in sterile compounding operations.
The article further explains that communication between pharmacists, healthcare providers, and patients remains an important part of safe compounded prescriptions. Compounding pharmacists review prescriptions carefully, confirm dosing instructions, and evaluate ingredient compatibility before preparation begins. This collaborative approach supports medication safety by reducing the risk of errors and ensuring treatments meet individual patient needs.
The article concludes that sterile compounding continues to play an important role in healthcare, particularly for patients requiring customized therapies that are unavailable through traditional manufacturing channels. Whether preparing IV medications, injectable therapies, or other sterile compounded medications, pharmacies rely on contamination prevention procedures and strict preparation standards to support patient care. The article notes that understanding how sterile compounding works can help patients feel more informed about the safety measures involved in preparing specialized medications.
What Sterile Compounding Means for Medication Safety features insights from Laura Temple, a compounding pharmacist expert at Laura’s Pharmacy in Azle, Texas, on HelloNation.
About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hellonation-article-highlights-sterile-compounding-and-medication-safety-with-insights-from-compounding-pharmacist-expert-laura-temple-302831275.html
SOURCE HelloNation
Technology
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Published
3 minutes agoon
July 21, 2026By
Regulatory demands are increasing in volume, complexity, and speed, leaving many organizations reliant on fragmented, manual approaches that slow response times and increase risk. New insights from Info-Tech Research Group show that organizations need to adopt more structured and scalable approaches to keep pace with regulatory change. The firm’s recently published blueprint, Build a Regulatory IT Response Engine, provides frameworks, tools, and step-by-step guidance to help organizations translate regulatory requirements into actionable IT controls and prioritized initiatives.
ARLINGTON, Va., July 21, 2026 /PRNewswire/ — Growing regulatory pressure across jurisdictions is forcing organizations to rethink how they interpret, prioritize, and execute compliance requirements. Many IT teams continue to operate with inconsistent processes and limited coordination, resulting in delayed initiatives and increased exposure to financial and reputational risk. Info-Tech’s blueprint, Build a Regulatory IT Response Engine, introduces a coordinated and repeatable approach to help IT leaders operationalize compliance and improve execution outcomes.
Info-Tech’s findings indicate that while organizations recognize the need for faster and more consistent regulatory response, they continue to face barriers such as fragmented interpretation of requirements, weak prioritization, and limited scalability. AI-enabled tools can help streamline analysis and accelerate response planning, but without a coordinated approach grounded in governance and human oversight, those benefits are difficult to realize.
“Regulatory response is becoming too complex to manage through disconnected, manual processes,” says Ahmad Jowhar, senior research analyst at Info-Tech Research Group. “IT leaders need a repeatable way to interpret requirements, prioritize action, and use AI to accelerate planning without losing the governance and oversight needed to execute effectively.”
Key Challenges IT Leaders Face in Regulatory Response
Despite ongoing investments in compliance, organizations continue to face systemic challenges that hinder effective execution. Info-Tech’s blueprint highlights several areas where IT and compliance leaders struggle most:
Fragmented and manual processes that slow regulatory interpretation and response.Inconsistent application of regulatory requirements across teams and jurisdictions.Poor prioritization of IT initiatives, leading to missed deadlines and duplicated effort.Limited scalability to manage increasing regulatory volume and complexity.Misalignment between compliance activities and broader business priorities.
Info-Tech’s Framework for Building a Regulatory IT Response Engine
To address these challenges, Info-Tech recommends a structured, AI-enabled approach that improves consistency, speed, and scalability. The firm’s Build a Regulatory IT Response Engine blueprint outlines the following key priorities for IT leaders:
Define the regulatory landscape: Establish organizational context, governance structures, and a centralized inventory of applicable regulations.Translate requirements into IT controls: Use AI-enabled analysis and structured assessments to convert regulatory obligations into actionable controls.Prioritize IT initiatives: Align initiatives based on cost, effort, impact, and regulatory timelines to reduce execution risk.Build and communicate a roadmap: Develop a clear, resource-aligned roadmap to guide execution and stakeholder alignment.Establish a repeatable process: Continuously monitor, adapt, and refine regulatory response capabilities to maintain compliance over time.
Organizations that adopt this structured approach can move from reactive compliance efforts to a more proactive and scalable model that shortens response timelines, reduces manual effort, and strengthens execution.
The firm’s Build a Regulatory IT Response Engine blueprint includes practical tools such as a Regulation Inventory Tool, a Regulatory Response IT Action Plan Tool, a Communication Deck Template, and a Compliance Program Framework. By applying these resources, IT leaders can standardize regulatory responses, improve prioritization, and help ensure compliance initiatives are executed on time and in alignment with business priorities.
For exclusive and timely commentary from Info-Tech’s experts, including Ahmad Jowhar, and access to the complete Build a Regulatory IT Response Engine blueprint, please contact pr@infotech.com.
About Info-Tech Research Group
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter.
To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform.
Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com.
For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cios-forced-to-rethink-manual-compliance-processes-as-regulatory-complexity-rises-says-info-tech-research-group-302831286.html
SOURCE Info-Tech Research Group
Technology
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Published
3 minutes agoon
July 21, 2026By
LOS GATOS, Calif., July 21, 2026 /PRNewswire/ — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and technology licensing company, announced today that it plans to release its second quarter 2026 financial results after the market closes on Tuesday, Aug. 4, 2026.
The company will host a live video Zoom webinar at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Tuesday, Aug. 4, 2026, to discuss the results. The live webinar can be accessed through Atomera’s investor relations website at https://ir.atomera.com. A replay of the webcast will be available for 12 months. To pre-register for the webinar, use the following link.
https://atomera.zoom.us/webinar/register/WN_OJFbTWe1SIyV69LLdDadCw
About Atomera
Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon Technology™ (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap. More information can be found at www.atomera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/atomera-to-announce-second-quarter-2026-financial-results-and-host-webinar-on-tuesday-august-4-2026-302830602.html
SOURCE Atomera Incorporated
HelloNation Article Highlights Sterile Compounding and Medication Safety With Insights From Compounding Pharmacist Expert Laura Temple
CIOs Forced to Rethink Manual Compliance Processes as Regulatory Complexity Rises, Says Info-Tech Research Group
Atomera to Announce Second Quarter 2026 Financial Results and Host Webinar on Tuesday, August 4, 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoTimed with the Canton Fair, Connexion ShenZhen 2026 Unveils Major Fourth-Edition Upgrades as a Greater Bay Area Mega Sourcing Event
-
Coin Market5 days agoBitcoin outlook improves amid 6% weekly gain: Can BTC bulls push higher?
-
Technology4 days agoGlobal Times: China sends fresh signal on global AI cooperation at WAIC
-
Coin Market4 days agoThe British Virgin Islands are a top crypto hub no one ever talks about: Here’s why
-
Coin Market5 days agoTrump teleprompter operator made $100K betting on Kalshi markets tied to speeches: ABC
-
Technology5 days agoGrand Bargain Project Announces Procedural Change that Will Turn Congress into a Problem-Solving Institution Within Days
-
Technology5 days agoDrake Expands End-to-End Professional Services with Launch of Drake Audit Defense™
-
Technology5 days agoTexas Instruments board declares third quarter 2026 quarterly dividend
